Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
In December 2025, J.P. Morgan upgraded Recursion Pharmaceuticals after REC-4881 showed rapid, durable polyp burden reductions and a favorable safety profile in familial adenomatous polyposis patients, ...
Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...
The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental.
A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.
Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to payments based on a ...
Since the 2000s, Google Search—and later YouTube and Discover—served as the primary discovery and monetization engines for digital publishing. This relationship was symbiotic, if lopsided. Two decades ...
Cornered in a part of Downtown Los Angeles swamped in contemporary art museums and performance centers, REDCAT has become a ...
The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback